Trials / Completed
CompletedNCT02397473
A Study Of Galcanezumab In Participants With Episodic Cluster Headache
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Cluster Headache
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 109 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the efficacy and safety of the study drug known as Galcanezumab in participants with episodic cluster headaches.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Galcanezumab | Administered SC |
| DRUG | Placebo | Administered SC |
Timeline
- Start date
- 2015-05-22
- Primary completion
- 2018-02-12
- Completion
- 2018-06-04
- First posted
- 2015-03-25
- Last updated
- 2019-09-09
- Results posted
- 2019-03-13
Locations
47 sites across 12 countries: United States, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02397473. Inclusion in this directory is not an endorsement.